Category: Uncategorized

A novel drug for activated phosphoinositide-3 kinase delta syndrome: Leniolisib

Active  name: Leniolisib Brand name: Joenja   Innovator name PHARMING TECHNOLOGIES BV Approval Date: March 24, 2023 Therapeutic activity:   phosphoinositide 3-kinase-delta inhibitor that is used to treat activated phosphoinositide 3-kinase delta syndrome Route of adminstration Tablet, oral Structure Chemical name 1-[(3S)-3- [[5,6,7,8-Tetrahydro-6-[6-methoxy-5-(trifluoromethyl)-3-pyridinyl]pyrido[4,3-d]pyrimidin4-yl]amino]-1-pyrrolidinyl]-1-propanone CAS 1354690-24-6(free base); 1354691-97-6 ( Phosphate salt) Dosage:   70 mg MDD […]

CAPIVASERTIB: Treatment for cancer

Active  name: Capivasertib   Brand name: Truqap   Innovator name ASTRAZENECA PHARMACEUTICAL LTD Approval Date: Nov 16, 2023 Therapeutic activity:   Capivasertib, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. Route of adminstration Tablet, […]

Back To Top